Stocktube video
04/09/2014

Summit plc CEO pleased with drug development progress

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: SUMM
Latest Price: 158.50p  (0.96% Ascending)
52-week High: 178.00p
52-week Low: 6.25p
Market Cap: 65.08M
1 year chart More charts
Deal SUMM Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Summit plc
www.summitplc.com
Deal Summit plc Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

 

Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the...

Read more
Pdf

Summit inks breakthrough Seglin deal with Bristol-Myers Squibb

September 11 2012, 7:05am In C1100, the group has a potentially breakthrough treatment for Duchenne Muscular Dystrophy. Its second major discovert, SMT 19969, is a highly potent anti-biotic designed to tackle the hospital superbug C.difficile.

 

Summit Corp (LON:SUMM) this morning unveiled a collaboration with one of the world’s largest pharmaceuticals companies that could eventually be worth US$30 million per product in research, development and regulatory milestone payments.

Initially Bristol-Myers Squibb will pay US$100,000 fee to access the company’s Seglin technology.

It is hoped these second generation immunosugars will provide a radical new platform to develop drugs for illnesses such as Alzheimers. 

The importance of proteins and nucleic acids is well established in drug discovery, but the targeting of carbohydrate biology remains largely underexploited.  Seglin technology hopes to redress the balance. 

The partnership is an early first step in the re-focused strategy set out by chief executive Glyn Edwards.

Last week he revealed he wanted “someone else to pick up the heavy lifting” on the exciting Seglin programme, which is still in the very early phase of development, to allow the company to focus on their two key drug candidates.

In C1100, the group has a potentially breakthrough treatment for Duchenne Muscular Dystrophy. Its second major discovert, SMT 19969, is a highly potent anti-biotic designed to tackle the hospital superbug C.difficile.

Edwards said this morning: “This agreement with Bristol-Myers Squibb further reinforces our strategy as we seek alternative ways to realise the value of our Seglin technology while we concentrate our resources on advancing our core Duchenne Muscular Dystrophy and C. difficile programmes.”

Under the terms of the agreement, Bristol-Myers will be responsible for the discovery stage research and will have the exclusive right to develop and commercialise any Seglin products that are identified.

The AIM listed group will receive afore mentioned technology access fee and is eligible for research, development and regulatory milestones of up to $30 million per product, plus royalties on worldwide sales of any products. 


 

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.